| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COX7A1 |
| Uniprot No | P24310 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-79aa |
| 氨基酸序列 | MQALRVSQALIRSFSSTARNRFQNRVREKQKLFQEDNDIPLYLKGGIVDNILYRVTMTLCLGGTVYSLYSLGWASFPRN |
| 预测分子量 | 9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COX7A1重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: "Characterization of human COX7A1 reveals mitochondrial localization and tissue-specific expression patterns"
**作者**: Smith J, et al.
**摘要**: 研究通过重组表达人源COX7A1蛋白，验证其在线粒体中的定位，并分析其在不同组织中的表达差异，发现其在心脏和骨骼肌中高表达，支持其与能量代谢的关联。
2. **文献名称**: "Recombinant COX7A1 production in E. coli for functional studies of cytochrome c oxidase assembly"
**作者**: Tanaka K, et al.
**摘要**: 报道了利用大肠杆菌系统高效表达并纯化重组COX7A1蛋白，结合体外复合体IV组装实验，证明其在细胞色素C氧化酶形成中的关键辅助作用。
3. **文献名称**: "COX7A1 deficiency disrupts mitochondrial supercomplex organization: Insights from recombinant protein rescue experiments"
**作者**: Lee S, et al.
**摘要**: 通过重组COX7A1蛋白回补实验，发现其缺失导致线粒体超复合体结构异常，揭示了该亚基在维持呼吸链结构完整性中的必要性。
---
注：上述文献为示例，实际检索建议通过PubMed或Web of Science以“COX7A1 recombinant”为关键词筛选近年研究。
**Background of COX7A1 Recombinant Protein**
Cytochrome c oxidase subunit 7A1 (COX7A1) is a nuclear-encoded component of mitochondrial complex IV (cytochrome c oxidase), the terminal enzyme in the mitochondrial electron transport chain (ETC). This enzyme catalyzes the transfer of electrons from cytochrome c to molecular oxygen, driving ATP synthesis via oxidative phosphorylation. COX7A1. part of the COX7A subfamily, is integral to the structural stability and catalytic efficiency of complex IV. It is ubiquitously expressed but notably abundant in tissues with high metabolic demands, such as skeletal muscle, heart, and brain.
Recombinant COX7A1 protein is produced using genetic engineering techniques, typically involving cloning the human *COX7A1* gene into expression vectors (e.g., bacterial or mammalian systems) followed by purification via affinity chromatography. Its production enables detailed studies of COX7A1’s role in ETC function, cellular energy metabolism, and disease mechanisms. Dysregulation of COX7A1 has been linked to mitochondrial disorders, neurodegenerative diseases, and cancer, highlighting its biomedical relevance.
Researchers utilize recombinant COX7A1 to investigate protein-protein interactions within complex IV, assess mutations affecting enzyme activity, and explore therapeutic strategies targeting mitochondrial dysfunction. It also serves as an antigen for antibody development or a standard in diagnostic assays. By providing a controlled, high-purity form of the protein, recombinant COX7A1 advances both basic and translational research, offering insights into mitochondrial biology and potential therapies for energy metabolism-related pathologies.
×
